Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.75 -0.13 (-0.13%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,530,285
Open 103.79
Bid (Size) 103.44 (2)
Ask (Size) 104.20 (10)
Prev. Close 103.88
Today's Range 102.65 - 104.01
52wk Range 96.36 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu 
Via Benzinga
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire

Performance

YTD
-6.65%
-6.65%
1 Month
+1.34%
+1.34%
3 Month
-4.47%
-4.47%
6 Month
-5.56%
-5.56%
1 Year
-4.62%
-4.62%

More News

Read More
Double Flops For Merck's Lung Cancer Studies
Via Benzinga
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
Price Over Earnings Overview: Merck & Co
Via Benzinga
5 Dividend Stocks That Recently Increased Their Payouts
Via The Motley Fool
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
Via Talk Markets
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
Analyst Ratings for Merck & Co
Via Benzinga
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
From Amazon.com, Inc.
Via Business Wire
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Announces First-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Via Benzinga
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
Via InvestorPlace
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
Via Benzinga
Merck to Acquire Caraway Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Three Solid Stocks That Still Have Plenty Of Growth Left
Via Talk Markets
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
Via Benzinga
Exposures Product Safety
FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer
Via Benzinga
Exposures Product Safety
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.